71 results about "Lymphoid Tumor" patented technology

The invention relates to a lymphoma prognosis prediction method and device based on a PET-CT marker and a medium, and the method comprises the following steps: obtaining a PET / CT image of a patient, inputting the PET / CT image into a lymphoma prognosis prediction model based on image-clinical-molecular typing, and obtaining a prognosis risk category; the lymphoma prognosis prediction model based on image-clinical-molecular typing is constructed according to PET-CT markers, clinical indexes and genetic typing data, the PET-CT markers are obtained by calculating a segmentation result of a PET / CT image of a patient according to a bimodal lesion segmentation network, and prognosis significance verification is performed through a K-M survival curve; the bimodal lesion segmentation network comprises an encoder and a decoder, the encoder performs feature extraction through a plurality of convolutional layers, and a channel smoothing layer is introduced after the last convolutional layer to fuse the extracted features. Compared with the prior art, tumor information can be accurately captured from PET / CT images, and lymphoma prognosis prediction is carried out in combination with genomics and clinical medicine.

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and / or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

The invention discloses a CAR-T treatment response intelligent prediction system based on medical images, and relates to the field of medical image analysis and tumor immunotherapy, and the system comprises a data integration module, a multi-modal feature extraction module, a prediction model construction module, a model optimization module, a clinical analysis module and an adverse reaction risk early warning module. The system integrates PET-CT, MRI, ultrasound and other multi-mode medical image data, and extracts the form, texture and metabolic characteristics of the tumor; constructing a treatment response prediction model by adopting a three-dimensional convolutional neural network; innovatively applying a differential geometry theory, constructing a medical image manifold structure and generating a tumor adversarial sample maintaining topological characteristics, and executing an adaptive optimization strategy by using a Riemannian metric space; accurate prediction of CAR-T treatment response of a lymphoma patient is realized, and adverse reaction risk early warning is carried out through brain and visceral organ image analysis.

The invention relates to a hetero (aromatic) ring substituted cyclic diamine compound, preparation thereof and application of the hetero (aromatic) ring substituted cyclic diamine compound in preparation of drugs for treating and / or preventing tumors. The structural formula of the compound is shown as (I). The compound has an obvious growth inhibition effect on tumor cells of leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophagus cancer, glioma, kidney cancer, nasopharynx cancer, liver cancer, stomach cancer, pancreatic cancer and the like. The compound disclosed by the invention has broad-spectrum anti-tumor activity; the compound has a good tumor inhibition effect and a PD-L1 protein degradation effect, and is a PD-L1 immunomodulator.

Disclosed are a novel polypeptide, a polypeptide derivative and the use thereof, which belong to the technical field of biomedicine. The present application specifically relates to a specific sequence, a discovery process, specific types of tumors to be resisted, a long-acting modification method and the use of the novel polypeptide, wherein the tumors include one or more of glioma, neuroblastoma, head and neck cancer, esophageal cancer, thyroid cancer, lung cancer, liver cancer, kidney cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, colon cancer, small intestine cancer, ileocecal cancer, gastric cancer, bladder cancer, pancreatic cancer, prostate cancer, cholangiocarcinoma, melanoma, sarcoma, myeloma, lymphoma and leukemia; and the specific use comprises the inhibition of the proliferation and / or metastasis of the above-mentioned tumor cells. The novel polypeptide has a wide therapeutic spectrum and important therapeutic value against various tumors.

We have discovered that allogeneic HSC-engineered human iNKT (3rdHSC-iNKT) cells display potent anti-GvHD functions, by eliminating antigen-presenting myeloid cells in vitro and in xenograft models, without negatively impacting tumor eradication by allogeneic T cells in preclinical models of lymphoma and leukemia. The 3rdHSC-iNKT cells closely resembled the CD4−CD8− / + subsets of endogenous human iNKT cells in phenotype and functionality. Embodiments of the invention harness these discoveries in new methods and materials for alleviating graft versus host disease.

This disclosure relates to methods and compositions for treating cancer including advanced solid tumor, a metastatic solid tumor or lymphoma using an inducible IL-12 prodrug.

To provide a composition and method for targeted treatment of cancer such as blood cancer.SOLUTION: Disclosed are a CAR polypeptide including a target domain selectively binding to a B lymphocyte antigen (e.g., hematological malignant tumor, e.g., CD19, CD20, and / or CD22 antigen related to leukemia and / or lymphoma), and a chimeric antigen receptor (CAR) T-cell which expresses the polypeptide, and can be used together with an adoptive cell transfer. Also disclosed is a method for bringing antitumor immunity to a subject having blood cancer accompanied by adoptive transfer of a CAR T-cell.SELECTED DRAWING: None

The present invention discloses a class of flavonoid derivatives, their preparation methods, and applications. The structural formula is shown in Formula I: wherein X is selected from CH and N, and R1 is selected from H. These compounds can significantly inhibit the activation of STAT3, a cell signaling pathway, at low doses. Experimental results show that these compounds can significantly inhibit the proliferation of various tumor cell lines, including lymphoma, multiple myeloma, cervical cancer, breast cancer, gastric cancer, lung cancer, and pancreatic cancer. They can specifically inhibit STAT3 signaling activation and the expression of the downstream target gene cyclinD1, indicating that these compounds have the potential to be developed as targeted anti-tumor drugs related to the STAT3 signaling pathway.

An oncolytic group B adenovirus suitable for use in the treatment of solid tumors, such as sarcoma, cancer and / or lymphoma, comprising a sequence of formula (I): 5 'ITR-B1-BA-B2-BX-BB-BY-B3-3' ITR (I) wherein: a first transgene encodes a polypeptide comprising a target sequence specific for a binding domain on a cell of a cell-based immunotherapy, a target sequence, such as a protein with a (exogenous) recombinant surface expression, such as a chimeric antigen receptor or NKG2D receptor, in particular wherein the target sequence specifically binds to the surface-expressed protein, more particularly the chimeric antigen receptor, on an immunotherapy cell; and the second transgene encodes a polypeptide comprising a molecule that promotes the cell-based immunotherapy to enter and transport within a tumor.

The application provides a novel DNA methylation marker TAGMe-5 for tumor identification and use thereof. The tumor marker TAGMe-5 of the application shows significant DNA methylation difference between cancer adjacent tissue and cancer tissue, and the difference has significant statistical significance, and the difference is shown in numerous tumors such as solid tumors and non-solid tumors. The solid tumors include lung cancer, liver cancer, prostate cancer, cervical cancer, endometrial cancer, urothelial carcinoma, biliary tract tumor, etc. The non-solid tumors include hematological tumors, lymphoma, etc. Therefore, the tumor marker of the application can be used for clinical screening of pan-cancer, molecular diagnosis, prognosis and efficacy evaluation.

The invention relates to the technical field of image data processing, in particular to a lymphoma-oriented fluorescence image and pathological section information fusion method. A first image and a second image of the lymphoma tissue sample are obtained, the first image is a bright field image, and the second image is a FISH image; in the first image, the difference degree between each cell and a normal cell and the difference degree between each tissue boundary and a normal tissue boundary are analyzed, and a cell anomaly index and a tissue anomaly index are obtained respectively; determining a slice anomaly index according to the cell anomaly index and the tissue anomaly index, and adjusting an initial block size based on the slice anomaly index to obtain a target block size; and taking the target block size as a block size, and fusing the first image and the second image by using a double-flow convolutional network to obtain a fused image. According to the invention, the image fusion effect of the FISH image and the bright field image of the lymphoma pathological section can be improved.

The invention relates to a compound containing a pyrrolopyrimidine structure or pharmaceutically acceptable salt thereof, a preparation method of the compound, a pharmaceutical composition containing the compound and medical application of the compound. The compound disclosed by the invention has the effect of specifically inhibiting BTK, has a relatively strong inhibition effect on TMD-8 lymphoma cells, has relatively high bioavailability, shows relatively strong inhibition activity on a TMD-8 tumor model, and can be used for preparing medicines for treating BTK function related diseases such as B cell malignant tumors, autoimmune diseases and the like.

This invention relates to the field of image data processing technology, specifically to a method for information fusion between fluorescence images and pathological sections of lymphoma. The method involves acquiring a first image and a second image of a lymphoma tissue sample; the first image is a bright-field image, and the second image is a FISH image. In the first image, the degree of difference between each cell and normal cells, as well as the degree of difference between each tissue boundary and normal tissue boundaries, are analyzed to obtain cell abnormality indices and tissue abnormality indices, respectively. Based on the cell abnormality indices and tissue abnormality indices, a section abnormality index is determined, and the initial block size is adjusted based on the section abnormality index to obtain a target block size. Using the target block size as the block size, a two-stream convolutional network is used to fuse the first image and the second image to obtain a fused image. This invention improves the image fusion effect between FISH images and bright-field images of lymphoma pathological sections.

The invention relates to a triple-effect T cell adapter for targeting T cell lymphoma TRBC1. The invention discloses a TRBC1-targeted triple-effect T cell adapter which is composed of an Fc region, a hinge region, a first Fab arm and a second Fab arm, and a third targeting module is covalently connected to the C end of the Fc region to form a Y-shaped triple-head antibody. The first Fab arm and the second Fab arm are respectively combined with TRBC1 and CD3, and the third Fab arm is combined with CD28 or CD137, so that three functions of tumor recognition, T cell recruitment and co-stimulation amplification are integrated. The two polypeptide chains are heterodimerized through CH3 region button mutation, and correct assembly is ensured. The structure supports module interchange, programmable regulation and control of synergistic signals, significantly enhances TRBC1 positive T cell lymphoma killing, reduces toxicity to normal T cells, has high activity and a wide safety window, and is suitable for preparation of related drugs.

This disclosure relates to methods and compositions for treating cancer, including advanced solid tumors, metastatic solid tumors, or lymphoma, using an inducible IL-12 prodrug. This disclosure relates to compositions and methods for treating cancer using an inducible IL-12 prodrug. This inducible IL-12 prodrug contains attenuated IL-12 and has a longer half-life compared to naturally occurring IL-12. Optionally, IL-12 may be mutein. IL-12 mutein may be aglycosylated or partially aglycosylated.

The application provides a lymphoma image data generation method based on conditional constraint and feature matching of a generative adversarial network, and is used for data enhancement of lymphoma images. The method first combines a label constraint, builds a full connection layer and four deconvolution layers for a generative model of WGAN-GP to generate images, then builds three convolution layers and a full connection layer for a discriminant model of WGAN-GP to identify whether the images are from the real or generated, and finally combines a feature matching method to establish a loss function, generates images with specified labels through the adversarial learning of the generative model and the discriminant model, so as to achieve the purpose of data enhancement. A large number of clinical cases are needed for the acquisition of lymphoma images, however, the method can solve the problem that workers are difficult to acquire specified type lymphoma image data in the prior art, further improves the work efficiency of workers, thereby reduces the working time of workers and improves the authenticity of the generated images.

The invention relates to the technical field of molecular biology, in particular to a molecular marker combination and a kit for B lymphoma cell detection or enrichment or PVRL prediction, diagnosis or prognosis, and B lymphoma cells are tumor cells of primary vitreoretinal lymphoma. Specifically, the invention provides a molecular marker combination capable of being used for detecting tumor cells of primary vitreous retinal lymphoma, and the molecular marker combination comprises ZBTB7A and CDKN2A.

The present invention belongs to the field of medical image processing technology, and specifically relates to a primary central nervous system lymphoma detection and classification method and system based on YOLOv8, including: collecting MRI image data of patients with primary central nervous system diffuse large B-cell lymphoma, intracranial metastasis, and glioblastoma; processing the MRI image data, screening out images containing tumors in the MRI images, and forming a data set with randomly selected patient images without tumors, and dividing the data set into a training set, a validation set, and a test set; annotating the images in the training set and the validation set; training a YOLOv8 target detection model; using classification loss to update the weight of the model; and evaluating the target detection and classification performance of the target detection model. The present invention can successfully detect PCNS-DLBCL tumors, and can be distinguished from GBM and BM at the same time, with high accuracy and robustness.

The invention discloses a composition for treating ABC type diffuse large B-cell lymphoma and application of the composition, and relates to the technical field of biological medicine. The composition comprises the chidamide and the hispidulin. According to the invention, a synergistic treatment system of the composition chidamide and hispidulin is constructed, and the problem of treatment of ABC type diffuse large B-cell lymphoma is accurately solved. According to the composition, through targeting double key targets of HDAC3 and PIM1, the synergistic interaction of epigenetic regulation and signal channel inhibition is realized, and the anti-tumor effect is remarkably improved. The invention successfully breaks through the bottleneck that the existing R-CHOP scheme is poor in curative effect and easy to relapse in the treatment of ABC subtype lymphoma, provides a brand new high-specificity treatment strategy for relapse or refractory ABC type diffuse large B-cell lymphoma, and has a wide clinical application prospect.

The invention relates to a multitask lymphoma segmentation method based on PET-CT image fusion. The multitask lymphoma segmentation method comprises the following steps: inputting and preprocessing data; constructing a multi-task collaborative learning framework comprising a classification and segmentation network structure module, a PET-CT multi-modal feature fusion module and a multi-stage joint attention mechanism module, and performing training; and inputting the preprocessed data into the trained multi-task collaborative learning framework to obtain a result. According to the method, the depth and precision of PET-CT image information fusion are improved, a multi-modal feature fusion strategy is adopted, PET and CT modal information is fused in the two levels of space and channel, the image expression ability is improved, and the model can better recognize tumor areas with fuzzy boundaries and complex structures.

The application discloses a compound capable of targeted degradation of MYC and application thereof, and belongs to the technical field of medicines. The compound can target degradation of MYC after entering a patient's body, thereby effectively inhibiting the proliferation of tumor cells such as lymphoma and osteosarcoma and cancer cells such as colorectal cancer, and having good anti-tumor effect and anticancer effect; the compound can also inhibit the proliferation of myelomonocytic leukemia cells in the patient's body, thereby providing a new treatment scheme for treating myelomonocytic leukemia; the compound has a synergistic effect when combined with doxorubicin, has better anti-tumor activity, and has a wide application prospect in the field of medicines.

Methods of treatment and / or prevention of tumours, preferably of solid tumours, more preferably of breast cancer, melanoma, bladder cancer, head and neck cancer, Hodgkin's lymphoma, kidney cancer, non-small cell lung cancer using fermented supernatant, or fractions thereof, of the Lactobacillus casei or paracasei species are disclosed. The species is the strain deposited according to the Budapest Treaty with No. CNCM I-5220 and / or includes in its DNA genome a DNA sequence essentially identical to one of: SEQ ID No 1 to 5.

The present invention provides a method for expanding tumor-infiltrating lymphocytes (TILs) (including peripheral blood lymphocytes and bone marrow-infiltrating lymphocytes) from the blood and / or bone marrow of patients with hematological malignancies (e.g., liquid tumors, including lymphomas and leukemias), and the use of the TILs so expanded in treating diseases (e.g., cancer and hematological malignancies).

The present invention relates to a glutarimide compound, the chemical structure of which is shown in the following formula (I): wherein L is selected from D and a glutarimide compound is selected from the present invention, which can simultaneously degrade BDR4 and GSPT1. The compound shows a good killing effect on blood system tumor cells (including multiple myeloma, lymphoma and leukemia), which is better than the clinical candidate drug CC-90009.

The present disclosure provides methods of treating lymphoma comprising administering a bispecific CD20×CD3 antibody to a patient in need thereof, wherein the patient is selected on the basis of exhibiting a modified level of circulating tumor (ct) DNA. In certain embodiments, the present disclosure provides methods of identifying a patient with lymphoma who is likely to respond favorably to therapy comprising a bispecific CD20×CD3 antibody.

The present description provides a hematological disorder (HD) assay panel for targeted detection of methylation patterns or variants specific to various hematological disorders, such as clonal hematopoiesis of indeterminate potential (CHIP) and blood cancers, such as leukemia, lymphoid neoplasms (e.g. lymphoma), multiple myeloma, and myeloid neoplasm. Further provided herein includes methods of designing, making, and using the HD assay panel for detection of various hematological disorders.

This invention discloses the use of the phenylalanyl-tRNA synthetase α subunit in the treatment of non-Hodgkin's lymphoma. Experiments have demonstrated that reducing or increasing the expression level of FARSA in non-Hodgkin's lymphoma cell lines can effectively regulate the cell cycle and proliferation of tumor cells. This invention provides a new target for the treatment of non-Hodgkin's lymphoma.

The invention discloses an interferon regulatory factor 4 (IRF4) inhibitor as shown in a formula (1) and a preparation method thereof, and a target product is prepared by taking dinorhydrin as a raw material through reactions such as TBS protection, 4, 4-dimethylation, TBS protection removal, oxidation, esterification, reduction, iodination, cyano substitution, Wittig, hydrolysis, esterification, amidation, condensation and the like. The invention further discloses an application of the IRF4 inhibitor in the aspect of treating multiple myeloma (MM), and further discloses an application of the IRF4 inhibitor in the aspect of treating multiple myeloma (MM). The compound can selectively inhibit the multiplication capacity of IRF4 high-expression myeloma cells, and has a good application prospect in treatment of IRF4 high-expression tumors such as multiple myeloma and lymphoma.

The present invention relates to a thyroid lymphoma prediction method and device based on machine learning, which belongs to the field of image processing technology and solves the problem of the lack of thyroid lymphoma prediction methods based on deep learning in the prior art. The specific steps include: annotating the thyroid ultrasound image with the lesion area segmented, including the lesion type label of lymphoma, to obtain the original data set; extracting the tumor imaging features of the original data set to obtain the initial features, and performing zero importance analysis and correlation screening in sequence to obtain the final screening features with high importance and low correlation; based on the final screening features and the annotated lesion type labels, using machine learning training to obtain a thyroid lymphoma prediction model; performing feature extraction on the thyroid ultrasound segmentation image to be tested with the suspected lesion area segmented, to obtain the corresponding final screening features; based on the corresponding final screening features, using the thyroid lymphoma prediction model to achieve accurate prediction of thyroid lymphoma.